Somatic gene mutation and human disease other than cancer

Mutation Research - Reviews in Mutation Research

Volumn 543, Issue 2, 2003, Pages 125-136

  Erickson, Robert P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Genetic syndromes; Mosaicism; Revertants; Skin manifestations

Indexed keywords

DNA;

ALBRIGHT SYNDROME; ANGIOOSTEOHYPERTROPHY SYNDROME; BLOOD DISEASE; BONE DISEASE; CANCER; CELL SEPARATION; DNA DETERMINATION; GENE MUTATION; GERM LINE; INCONTINENTIA PIGMENTI; LETHALITY; MOSAICISM; MULTIPLE CANCER; NEUROFIBROMATOSIS; OSTEOCHONDROMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; REVERTANT; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; SOMATIC MUTATION; VASCULAR TISSUE;

EID: 0037342752     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(03)00010-3     Document Type: Review

References (107)

1. Knudson A.G. Jr., Strong L.C. Mutation and cancer: neuroblastoma and pheochromocytoma. Am. J. Hum. Genet. 24:1972;514-532.
2. Kinzler K.W., Vogelstein B. Landscaping the cancer terrain. Science. 280:1998;1036-1037.
3. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
4. Paller A.S., Snyder A.J., Chan Y.-M., Y Q.-C., Hutton E., Tadini G., Fuchs E. Genetic and clinical mosaicism in a type of epidermal nevus. N. Engl. J. Med. 331:1994;1408-1415.
5. Warburton D., Yu C.-Y., Kline J., Stein Z. Mosaic autosomal trisomy in cultures from spontaneous abortions. Am. J. Hum. Genet. 30:1978;609-617.
6. Reddy K.S., Blakemore K.J., Stetten G., Corson V. The significance of trisomy 7 mosacism in chorionic villus cultures. Prenatal Diagnosis. 10:1990;417-423.
7. Kalousek D.K., Vekemans M. Confined placental mosaicism. J. Med. Genet. 33:1996;529-533.
8. Cariello N.F., Skopek T.R. Analysis of mutations occurring at the human hprt locus. J. Mol. Biol. 231:1993;41-57.
9. Cariello N.F., Douglas G.R., Gorelick N.J., Hart D.W., Wilson J.D., Soussi T. Databases and software for the analysis of mutations in the human p53 gene human hprt gene and both the lacI and laxZ gene in transgenic rodents. Nucleic Acids Res. 26:1998;198-199.
10. Tischfield J.A., Engle S.J., Gupta P.K., Bye S., Boyadjiev S., Shao C., O'Neill P., Albertini R.J., Stambrook P.J., Sahota A.S. Germline and somatic mutation at the APRT locus of mice and man. Adv. Exp. Med. Biol. 370:1994;661-664.
11. Colgin L.M., Hackmann A.F.M., Edmond M.J., Monnat R.J. Jr. The unexpected landscape of in vivo somatic mutation in a human epithelial cell lineage. Proc. Natl. Acad. Sci. U.S.A. 99:2002;1437-1442.
12. Cervantes R.B., Stringer J.R., Shao C., Tischfield J.A., Stambrook P.J. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc. Natl. Acad. Sci. U.S.A. 99:2002;3586-3590.
13. Ao A.M., Bielanska M., Chian R.C., Tan S.L. Chromosome abnormalities in spare preimplantation embryos from in vitro maturation (IVM) cycles. Fertil. Steril. 74:2000;S173-S173.
14. F. von Recklinghausen, Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen, Augsut Hirschwald, Berlin, 1882.
15. F.W. Crowe, W.J. Schull, J.V. Neel, A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis, Charles C Thomas, Springfield, IL, 1956.
16. Lisch K. Ueber Beteiligung der Augen, Insbesondere das Vorkommen von Irisknotchen bei der Neurofibromatose (Recklinghausen). Augenheilkunde. 93:1937;137-143.
17. Zehavi C., Romano A., Goodman R.M. Iris (Lisch) nodules in neurofibromatosis. Clin. Genet. 29:1986;51-55.
18. Otsuka F., Kawashima T., Imakado S., Usuki Y., Hon-mura S. Lisch nodules and skin manifestation in neurofibromatosis type 1. Arch. Derm. 137:2001;232-233.
19. Holt J.F. Neurofibromatosis in children. Am. J. Roentgen. 130:1978;615-639.
20. Hofman K.J., Harris E.L., Bryan R.N., Denckla M.B. Neurofibromatosis in children. J. Pediatr. 124:1994;S1-S8.
21. Legius E., Descheemaeker M.J., Steyaert J., Spaepen A., Vlietinck R., Casaer P., Demaerel P., Fryns J.P. Neurofibromatosis type 1 in childhood: correlation of MRI finding with intelligence. J. Neurol. Neurosurg. Psychiatr. 59:1995;638-640.
22. Hamilton S.J., Friedman J.M. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin. Genet. 58:2000;341-344.
23. Erickson R.P., Wooliscroft J., Allen R.J. Familial occurrence of intracranial arterial occlusive disease (moyamoya) in neurofibromatosis. Clin. Genet. 18:1980;191-196.
24. Zonana J., Weleber R.G. Segmental neurofibromatosis and iris hamartomata (Lisch nodules). Proc. Greenwood Genet. Control. 3:1984;140-141. (Abstract).
25. Nicolls E.M. Somatic variation and multiple neurofibromatosis. Hum. Hered. 19:1969;473-479.
26. Miller R.M., Sparkes R.S. Segmental neurofibromatosis. Arch. Derm. 113:1977;837-838.
27. Combemale P., Abitan R., Kanitakis J. Segmental neurofibromatosis: report of two cases and critical review of the literature. Eur. J. Derm. 4:1994;194-201.
28. V.M. Riccardi, J.E. Eichner, Neurofibromatosis: Phenotype, Natural History and Pathogenesis, Johns Hopkins University Press, Baltimore, MD, 1986.
29. Viskochil D., Buchberg A.M., Xu G., Cawthon R.M., Stevens J., Wolff R.K., Culver M., Carey J.C., Copeland N., Jenkins N.A., White R., O'Connell P. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 62:1990;187-192.
30. Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., Brownstein B.H., Collins F.S. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 249:1990;181-186.
31. Tinschert S., Naumann I., Stegmann E., Buske A., Kaufmann D., Thiel G., Jenne D.E. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur. J. Hum. Genet. 8:2000;455-459.
32. Colman S.D., Rasmussen S.A., Ho V.T., Abernathy C.R., Wallace M.R. Somatic mosaicism in a patient with nuerofibromatosis type 1. Am. J. Hum. Genet. 58:1996;484-490.
33. Ingordo V., D'Andria G., Mendecini S., Grecucci M., Baglivo A. Segmental neurofibromatosis: is it uncommon or underdiagnosed? Arch. Derm. 131:1995;959-960.
34. Wolkenstein P., Mahmoudi A., Zeller J., Revuz J. More on the frequency of segmental neurofibromatosis. Lett. Arch. Derm. 131:1995;1465.
35. Jadayel D., Fain P., Upadhyaya M., Ponder M.A., Hudson S.M., Carey J., Fryer A., Mathew C.G., Barker D.F., Ponder B.A.J. Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature. 343:1990;558-559.
36. Evans D.G.R., Wallace A.J., Wu C.L., Trueman L., Ramsden R.T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lesson from type 2 neurofibromatosis. Am. J. Hum. Genet. 63:1998;727-736.
37. McCune D.J., Bruch H. Progress in pediatrics: osteodystrophia fibrosa. Am. J. Dis. Child. 54:1937;806-848.
38. Albright F., Butler A.M., Hampton A.O., Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: report of five cases. N. Engl. J. Med. 216:1937;727-746.
39. Albright F., Scoville B., Sulkowitch H.W. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation, and a gonadal dysfunction: further observations including the report of two more cases. Endocrinology. 22:1938;411-421.
40. de Sanctis C., Lala R., Matarazzo P., Balsamo A., Bergamaschi R., Cappa M., Cisternio M., de Sanctis V., Lucci M., Franzese A., Ghizzoni L., Pasquino A.M., Segni M., Rigon F., Saggese G., Bertelloni S., Buzi F. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J. Pediatr. Endocrinol. Metab. 12:1999;817-826.
41. Lichtenstein L., Jaffe H.L. Fibrous dysplasia of the bone: a condition affecting one, several or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch. Path. 33:1942;777-816.
42. Hamilton C.R. Jr., Maloof F. Unusual types of hyperthyroidism. Medicine. 52:1973;195-213.
43. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin. Genet. 29:1986;321-324.
44. Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Eng. J. Med. 325:1991;1688-1695.
45. Schwindinger W.F., Francomano C.A., Levine M.A. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G-protein of adenylyl cyclase in McCune-Albright syndrome. Proc. Natl. Acad. Sci. U.S.A. 89:1992;5152-5156.
46. Cohen M.M. Jr., Howell R.E. Etiology of fibrous dysplasia and McCune-Albright syndrome. Int. J. Oral Maxillofac. Surg. 28:1999;366-371.
47. Cohen M.M. Jr. Fibrous dysplasia is a neoplasm. Am. J. Med. Genet. 98:2001;290-293.
48. Shenker A., Weinstein L.S., Sweet D.E., Spiegel A.M. An activating Gsa mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 79:1994;750-755.
49. Bianco P., Riminucci M., Majolagbe A., Kuznetsov S.A., Collins M.T., Mankani M.H., Corsi A., Bone H.G., Wientroub S., Spiegel A.M., Fisher L.W., Robey P.G. Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J. Bone Miner. Res. 15:2000;120-128.
50. Mahoney J.F., Urakaze M., Hall S., DeGasperi R., Chang H.-M., Sugiyama E., Warren C.D., Borowitz M., Nicholson-Weller A., Rosse W.F., Yeh E.T.H. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood. 79:1992;1400-1403.
51. Hirose S., Ravi L., Prince G.M., Rosenfeld M.G., Silber R., Andresen S.W., Hazra S.V., Medof M.E. Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6025-6029.
52. Takahashi M., Takeda J., Hirose S., Hyman R., Inoue N., Miyata T., Ueda E., Kitani T., Medof M.E., Kinoshita T. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 177:1993;517-521.
53. Miyata T., Takeda J., Iida Y., Yamada N., Inoue N., Takahashi M., Maeda K., Kitani T., Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 259:1993;1318-1320.
54. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 73:1993;703-711.
55. Araten D.J., Nafa K., Pakdeesuwan K., Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5209-5214.
56. Luzzatto L., Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr. Opin. Hematol. 3:1996;101-110.
57. Luzzatto L., Bessler M., Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell. 88:1997;1-4.
58. Dunn D.E., Yu J., Nagarajan S., Devetten M., Weichold F.F., Medof M.E., Young N.S., Liu J.M. A knock-out model of paroxysmal nocturnal hemoglobinuria: pig-a (-) hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins. Proc. Natl. Acad. Sci. U.S.A. 93:1996;7938.
59. Rosti V., Tremmi G., Soares V., Pandolfi P.P., Luzzatto L., Bessler M. Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J. Clin. Invest. 100:1997;1028.
60. Keller P., Tremml G., Rosti V., Bessler M. X inactivation and somatic cell selection resuce female mice carrying a Piga-null mutation. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7479-7483.
61. Sulzberger M.B. Incontinentia Pigmenti [Bloch-Sulzberger]: report of an additional case, with comment on possible relation to a new syndrome of familial and congenital anomalies. Arch. Dermatol. 38:1938;57-69.
62. International Incontinentia Pigmenti Foundation, The, Genomic rearrangement in NEMO impairs NF-kB activation and is a cause of incontinentia pigmenti, Nature 405 (2000) 466-472.
63. Carney R.G. Incontinentia pigmenti. A world statistical analysis. Arch. Dermatol. 112:1976;535-542.
64. Mansour S., Woffendin H., Mitton S., Jeffrey I., Jakins T., Kenwrick S., Murday V.A. Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection. Am. J. Med. Genet. 99:2001;172-177.
65. Zonana J., Elder M.E., Schneider L.C., Orlow S.J., Moss C., Golabi M., Shapira S.K., Farndon P.A., Wara D.W., Emmal S.A., Ferguson B.M. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am. J. Hum. Genet. 67:2000;1555-1562.
66. International IP Consortium, The, Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome, Am. J. Hum. Genet. 69 (2001) 1210-1217.
67. M.M. Cohen Jr., P.W. Hayden, A newly recognized hamartomatous syndrome, in: J.J. O'Donnel, B.D. Hall (Eds.), Penetrance and Variability in Malformation Syndromes, The National Foundation - March of Dimes, BD:OAS XV (5B), 1979, pp. 291-296.
68. Wiedmann H.-R., Burgio G.R., Aldenhoff P., Kunze J., Kaufmann H.J., Schirg E. The Proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly, skull anomalies and possible accelerated growth and visceral affections. Eur. J. Pediatr. 140:1983;5-12.
69. Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J. Am. Acad. Dermatol. 16:1987;899-906.
70. Tibbles J.A.R., Cohen M.M. Jr. Proteus syndrome: the elephant man diagnosed. Br. Med. J. 293:1986;683-685.
71. Cohen M.M. Jr. Proteus Syndrome: clinical evidence for somatic mosaicism and selective review. Am. J. Med. Genet. 47:1993;645-652.
72. Gorlin R.J. Proteus syndrome. J. Clin. Dysmorphol. 2:1984;8-9.
73. Cohen M.M. Jr. Understanding Proteus syndrome, unmasking the elephant man, and stemming elephant fever. Neurofibromatosis. 1:1988;260-280.
74. Biesecker L.G., Peters K.F., Darling T.N., Choyke P., Hill S., Schimke N., Cunningham M., Meltzer P., Cohen M.M. Jr. Clinical differentiation between Proteus syndrome and hemihyperplasia: description of a distinct form of hemihyperplasia. Am. J. Med. Genet. 79:1998;311-318.
75. Biesecker L.G., Happle R., Mulliken J.B., Weksberg R., Graham J.M. Jr., Viljoen D.L., Cohen M.M. Jr. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am. J. Med. Genet. 84:1999;389-395.
76. C.E. Schwartz, A.M. Brown, V.M. Der Kaloustian, C.C. McGill, R.A. Saul, DNA fingerprinting: the utilization of minisatellite probes to detect a somatic mutation in the Proteus syndrome, in: T. Burke, G. Dolf, A.J. Jeffreys, R. Wolff (Eds.), DNA Fingerprinting: Approaches and Applications, Birkhauser, Basel, Switzerland, 1991, pp. 95-105.
77. Klippel M., Trénaunay P. Du Noevus variquex osteohypertrophiques. Arch. Gen. Med. 185:1900;641-672.
78. Cohen M.M. Jr. Klippel-Trenaunay syndrome. Am. J. Med. Genet. 93:2000;171-175.
79. Baskerville P.A., Ackroyd J.S., Browse N.L. The etiology of the Klippel-Trénaunay syndrome. Ann. Surg. 202:1985;624-627.
80. Lindenauer S.M. The Klippel-Trénaunay syndrome: varicosity, hypertrophy and hemangioma with no ateriovenous fistula. Ann. Surg. 162:1965;303-314.
81. A. Malfucci, Di un caso di encondroma ed angioma multiple. Constribuzione all genesi embrionale dei tumor, Mov. Med. Chir. 3 (1881) 399-412, 565-575.
82. Hall J.G. Somatic mosaicism: observations related to clinical genetics. Am. J. Hum. Genet. 43:1988;355-363.
83. Cohn D.H., Starman B.J., Blumberg B., Byers P.H. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a dominant mutation in a human type I collagen gene (COL1A1). Am. J. Hum. Genet. 46:1990;591-601.
84. Wallis G.A., Starman B.J., Zinn A.B., Byers P.H. Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the α1(I) gene (COL1A1) of type I collagen in a parent. Am. J. Hum. Genet. 46:1990;1034-1040.
85. Edwards M.J., Wenstrup R.J., Byers P.H., Cohn D.H. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a mutation in the COL1A2 gene of type I collagen. The mosaic parent exhibits phenotype features of a mild form of the disease. Hum. Mutat. 1:1992;47-54.
86. Passos-Bueno M.R., Bakker E., Kneppers A.L., Takata R.I., Rapaport D., den Dunnen J.T., Zatz M., van Ommen P.J. Different mosaicism frequencies for proximal and distal Duchenne muscular dystrophy (DMD) mutations indicate difference in etiology and recurrence risk. Am. J. Hum. Genet. 51:1992;1150-1155.
87. Froissart R., Maire I., Bonnet V., Levade T., Bozon D. Germline and somatic mosaicism in a female carrier of Hunter disease. J. Med. Genet. 34:1997;137-140.
88. Sippel K.C., Fraioli R.E., Smith G.D., Schalkoff M.E., Sutherland J., Gallie B.L., Dryja T.P. Frequency of somatic and germline mosaicism in retinoblastoma: implications for genetic counseling. Am. J. Hum. Genet. 62:1998;610-619.
89. Putnam E.A., Park E.-S., Aalfs C.M., Hennekam R.C.M., Milewicz D.M. Parental somatic and germ-line mosaicism for a FBN2 mutation and analysis of FBN2 transcript levels in dermal fibroblasts. Am. J. Hum. Genet. 60:1997;818-827.
90. Ketterling R.P., Vielhaber E., Li X., Drost J., Schaid D.J., Kasper C.K., Phillips III J.A., Koerper M.A., Kim H., Sexauer C., Gruppo R., Ambriz R., Paredes R., Sommer S.S. Germline origins in the human F9 gene: frequent G:C-A:T mosaicism and increased mutations with advanced maternal age. Hum. Genet. 105:1999;629-640.
91. Leuer M., Oldenburg J., Lavergne J.-M., Ludwig M., Fregin A., Eigel A., Ljung R., Goodeve A., Peake I., Olek K. Somatic mosaicism in hemophilia A: a fairly common event. Am. J. Hum. Genet. 69:2001;75-87.
92. Becker J., Schwaab R., Möller-Taube A., Schwaab U., Schmidt W., Brackmann H.H., Grimm T., Olek K., Oldenburg J. Characterization of the factor VIII defect in 147 patients with sporadic hemophilia a: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am. J. Hum. Genet. 58:1996;657-670.
93. Jonkman M.F., Scheffer H., Stulp R., Pas H.H., Nijenhuis M., Heeres K., Owaribe K., Pulkkinen L., Uitto J. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 88:1997;543-551.
94. Kvittingen E.A., Rootwelt H., Berger R., Brandtzaeg P. Self-induced correction of the genetic defect in tyrosinemia type I. J. Clin. Invest. 94:1994;1657-1661.
95. Stephan V., Wahn V., Le Deist F., Dirksen U., Broker B., Muller-Fleckenstein I., Horneff G., Schroten H., Fischer A., de Saint Basile G. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335:1996;1563-1567.
96. Cavazzano-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.-L., Bousso P., Le Deist F., Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:2000;669-672.
97. Hirschhorn R., Yang D.R., Puck J.M., Huie M.L., Jiang C.-K., Kurlandsky E.L. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 13:1996;290-295.
98. Wada T., Schurman S.H., Otsu M., Garabedian E.K., Ochs H.D., Nelson D.L., Candotti F. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8697-8702.
99. Waisfisz Q., Morgan N.V., Savino M., de Winter J.P., van Berkel C.G.M., Hoatlin M.E., Ianzano L., Gibson R.A., Arwert F., Savoia A., Mathew C.G., Pronk J.C., Joenje H. Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat. Genet. 22:1999;379-383.
100. Lo Ten Foe J.R., Kwee M.L., Rooimans M.A., Oostra A.B., Veermans A.J.P., van Weel M., Pauli R.M., Shahidi N.T., Dokal I., Roberts I., Altay C., Gluckman E., Gibson R.A., Mathew C.G., Arwert F., Joenje H. Somatic mosaicism in fanconi anemia: molecular basis and clinical significance. Eur. J. Hum. Genet. 5:1997;137-148.
101. Klein C.J., Coovert D.D., Bulman D.E., Ray P.N., Mendell J.R., Burghes A.H.M. Somatic reversion/suppression in duchenne muscular dystrophy (DMD): evidence supporting a frame restoring mechanism in rare dystrophin-positive fibers. Am. J. Hum. Genet. 50:1992;950-959.
102. Sherratt T.G., Vulliamy V., Dubowitz V., Sewry C.A., Strong P.N. Exon skipping and translation in patients with frame shift deletions in the dystrophin gene. Am. J. Hum. Genet. 53:1993;1007-1015.
103. Melis M.A., Cau M., Congiu R., Puddu R., Muntoni F., Cao A. Germinal mosaicism in a duchenne muscular dystrophy family; implications for genetic counseling. Clin. Genet. 43:1993;247-249.
104. Lund A.M., Schwartz M., Skovby F. Genetic counseling and prenatal diagnosis of osteogenesis imperfecta caused by paternal mosaicism. Prenat. Diagn. 16:1996;1032-1038.
105. Bruttini M., Vitelli F., Meloni I., Rizzari G., Volpe M.D., Mazzucco G., Marchi M.D., Renieri A. Mosiacism in alport sundrome with genetic counseling. J. Med. Genet. 37:2000;717-719.
106. Filocamo M., Bonuccelli G., Mazzotti R., Corsolini F., Stroppiano M., Regis S., Gatti R. Somatic mosaicism in a patient with Gaucher disease type 2: implication for genetic counseling and therapeutic decision-making. Blood Cells Mol. Dis. 26:2000;611-612.
107. Boehmer A.L., Brinkmann A.O., Niermeijer M.F., Bakker L., Halley D.J., Drop S.L. Germ line and somatic mosaicism in the androgen insensitivity syndrome: implications for genetic counseling. Am. J. Hum. Genet. 60:1997;1003-1006.